#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.
“What we try to do is quite simple. We try to find drugs that will slow aging and extend mouse lifespan.” —Rich Miller
Do GLP-1 receptor agonists improve cardiovascular health independently of weight loss?
A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that’s not the question we ought to be asking.
#279 – AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins
“It is worth noting, and this is a very important question, that it does not appear that the effect of statins on insulin resistance is a function of lipids being lowered.” —Peter Attia
#277 ‒ Food allergies: causes, prevention, and treatment with immunotherapy | Kari Nadeau, M.D., Ph.D.
“What I love about the immune system is it can be trained, and you just need to know how to train it.” —Kari Nadeau
Is testosterone replacement therapy both safe and effective in men with higher cardiovascular risk factors?
An assessment of the results from the long-awaited TRAVERSE trial
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
Could a psoriasis drug find new purpose in treating alcohol use disorder?
Recent pilot research suggests that the psoriasis drug apremilast may have promise in curbing excessive drinking in those with alcohol use disorder.
#275 – AMA #52: Hormone replacement therapy: practical applications and the role of compounding pharmacies
“The sum total of lives that have been saved due to less breast cancer as a result from the lack of HRT for the past 20 years is exactly zero.” —Peter Attia
Could an antihypertensive drug have independent benefits for longevity?
A recent animal study indicates that the antihypertensive drug rilmenidine has impressive effects on lifespan, but without further evidence, this story seems like another “fountain of youth” myth.
#274 – Performance-enhancing drugs and hormones: risks, rewards, and broader implications for the public | Derek: More Plates, More Dates
“There’s no drug that’s purely selective exactly where you want and it’s perfect.” —Derek – More Plates More Dates